Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RXRA | P19793 | 5/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | LIPE | Q05469 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4126578 | 0.96 | L3MBTL1 (0.47) | L3MBTL1TDP1MRGPRX4KMT2AMAPK1 | |
| SCHEMBL4143275 | 0.84 | L3MBTL1 (0.39) | L3MBTL1TDP1MRGPRX4KMT2AMAPK1 | |
| SCHEMBL7076311 | 0.84 | MRGPRX4 (0.46) | L3MBTL1TDP1MRGPRX4KMT2AMAPK1 | |
| SCHEMBL7078746 | 0.84 | MRGPRX4 (0.46) | L3MBTL1TDP1MRGPRX4KMT2AMAPK1 | |
| SCHEMBL7716832 | 0.83 | L3MBTL1 (0.40) | L3MBTL1TDP1MRGPRX4KMT2AMAPK1 | |
| SCHEMBL4143051 | 0.82 | MAPK1 (0.46) | L3MBTL1TDP1MRGPRX4KMT2AMAPK1 | |
| SCHEMBL7073751 | 0.82 | MRGPRX4 (0.47) | L3MBTL1TDP1MRGPRX4KMT2AMAPK1 | |
| SCHEMBL27480518 | 0.81 | KMT2A (0.43) | L3MBTL1MRGPRX4KMT2AMAPK1RAB9A | |
| SCHEMBL27480517 | 0.81 | KMT2A (0.43) | L3MBTL1MRGPRX4KMT2AMAPK1RAB9A | |
| SCHEMBL4139449 | 0.80 | L3MBTL1 (0.40) | L3MBTL1TDP1MRGPRX4KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090209598-A1 | Resorcine Derivatives and Their Use as Pesticides | BASF SE (DE) | 2009-08-20 | — | — | US | disclosed |
| EP-1951649-A2 | RESORCINE DERIVATIVES AND THEIR USE AS PESTICIDES | BASF SE (DE) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007054558-A2 | RESORCINE DERIVATIVES AND THEIR USE AS PESTICIDES | BASF SE (DE) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209598-A1 | Resorcine Derivatives and Their Use as Pesticides | NR2C2, NR2E1, NR4A2 | L3MBTL1 476/4885TDP1 3818/4885MRGPRX4 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.